MXC: $0.053
What We Believe

We believe that Phytomedicine will effectively treat previously unmet medical needs and improve the lives of patients, impacting public health across the world.

MGC embraces this by creating Phytocannabinoid-based medicine products and providing them in targeted markets. These products are registered for sale and leverage the Company’s own proprietary medical cannabis formula through clinical trials in Europe, Israel and Australia. In addition, tertiary and supplementary revenue streams solidify our presence in the market.

This enables future medical product sales across the European Union, Australia, and other geographies, following the requisite legal and regulatory approvals.

Our Vision

To be a global leader in Phytocannabinoid-based medicines within the biopharmaceutical industry.

MGC Pharma’s goal is to facilitate the transformation of Phytocannabinoids into true medicinal product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and contribute to improved public health. MGC Pharma aims to build a responsible and profitable industry.

Our Mission

To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable Phytocannabinoid Derived Medicines of the Highest Regulatory Compliance for Targeted global markets and patients

ASX: MXC
$0.053
Monday, 17 May 2021
Latest Announcements
14/5/21Appendix 3G x 3 14/5/21Appendix 2A 7/5/21FURTHER FINDINGS ON ARTEMIC AS ANTI-INFLAMMATORY AGENT 6/5/21Trading Halt 6/5/21Pause in Trading 4/5/21$1M ORDER FOR ARTEMIC RESCUE FROM SWISS PHARMACAN 28/4/21ARTEMIC SUBMITTED TO HEALTH CANADA

Australia
Pharma Corporate & Financial Headquarters
Slovenia
Pharma European Operational Headquarters
UK
European Corporate Headquarters
Who
What
Why
Contact Us